190 related articles for article (PubMed ID: 34801627)
1. Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists.
de Oliveira AA; Vergara A; Wang X; Vederas JC; Oudit GY
Peptides; 2022 Jan; 147():170697. PubMed ID: 34801627
[TBL] [Abstract][Full Text] [Related]
2. Targeting Apelinergic System in Cardiometabolic Disease.
Guo R; Rogers O; Nair S
Curr Drug Targets; 2017; 18(15):1785-1791. PubMed ID: 27296311
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of apelin and Elabela in cardiovascular disease.
Gao S; Chen H
Biomed Pharmacother; 2023 Oct; 166():115268. PubMed ID: 37562237
[TBL] [Abstract][Full Text] [Related]
4. Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications.
Chatterjee P; Gheblawi M; Wang K; Vu J; Kondaiah P; Oudit GY
Clin Sci (Lond); 2020 Sep; 134(17):2319-2336. PubMed ID: 32901821
[TBL] [Abstract][Full Text] [Related]
5. Targeting the apelin pathway as a novel therapeutic approach for cardiovascular diseases.
Zhong JC; Zhang ZZ; Wang W; McKinnie SMK; Vederas JC; Oudit GY
Biochim Biophys Acta Mol Basis Dis; 2017 Aug; 1863(8):1942-1950. PubMed ID: 27825851
[TBL] [Abstract][Full Text] [Related]
6. The biological function of ELABELA and APJ signaling in the cardiovascular system and pre-eclampsia.
Liu Y; Wang L; Shi H
Hypertens Res; 2019 Jul; 42(7):928-934. PubMed ID: 30626933
[TBL] [Abstract][Full Text] [Related]
7. The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.
Marsault E; Llorens-Cortes C; Iturrioz X; Chun HJ; Lesur O; Oudit GY; Auger-Messier M
Ann N Y Acad Sci; 2019 Nov; 1455(1):12-33. PubMed ID: 31236974
[TBL] [Abstract][Full Text] [Related]
8. Targeting the apelin system for the treatment of cardiovascular diseases.
Chapman FA; Maguire JJ; Newby DE; Davenport AP; Dhaun N
Cardiovasc Res; 2023 Dec; 119(17):2683-2696. PubMed ID: 37956047
[TBL] [Abstract][Full Text] [Related]
9. International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.
Read C; Nyimanu D; Williams TL; Huggins DJ; Sulentic P; Macrae RGC; Yang P; Glen RC; Maguire JJ; Davenport AP
Pharmacol Rev; 2019 Oct; 71(4):467-502. PubMed ID: 31492821
[TBL] [Abstract][Full Text] [Related]
10. Apelin C-Terminal Fragments: Biological Properties and Therapeutic Potential.
Pisarenko OI; Studneva IM
Biochemistry (Mosc); 2023 Nov; 88(11):1874-1889. PubMed ID: 38105205
[TBL] [Abstract][Full Text] [Related]
11. The apelin/APJ system as a therapeutic target in metabolic diseases.
Castan-Laurell I; Masri B; Valet P
Expert Opin Ther Targets; 2019 Mar; 23(3):215-225. PubMed ID: 30570369
[TBL] [Abstract][Full Text] [Related]
12. The apelinergic-axis in human preeclamptic pregnancies: A systematic review.
Georgiadou D; Afink GB; van Dijk M
Pregnancy Hypertens; 2019 Jul; 17():148-157. PubMed ID: 31487633
[TBL] [Abstract][Full Text] [Related]
13. Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo.
Read C; Yang P; Kuc RE; Nyimanu D; Williams TL; Glen RC; Holt LJ; Arulanantham H; Smart A; Davenport AP; Maguire JJ
Basic Clin Pharmacol Toxicol; 2020 Jun; 126 Suppl 6():96-103. PubMed ID: 30901161
[TBL] [Abstract][Full Text] [Related]
14. Essential Role of the ELABELA-APJ Signaling Pathway in Cardiovascular System Development and Diseases.
Zhou S; Wang J; Wang Q; Meng Z; Peng J; Song W; Zhou Y; Chen S; Chen F; Sun K
J Cardiovasc Pharmacol; 2020 Apr; 75(4):284-291. PubMed ID: 32000202
[TBL] [Abstract][Full Text] [Related]
15. The role of apelinergic system in metabolism and reproductive system in normal and pathological conditions: an overview.
Mehri K; Hamidian G; Zavvari Oskuye Z; Nayebirad S; Farajdokht F
Front Endocrinol (Lausanne); 2023; 14():1193150. PubMed ID: 37424869
[TBL] [Abstract][Full Text] [Related]
16. The Apelinergic System in Pregnancy.
Pécheux O; Correia-Branco A; Cohen M; Martinez de Tejada B
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175743
[TBL] [Abstract][Full Text] [Related]
17. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.
Kuba K; Sato T; Imai Y; Yamaguchi T
Peptides; 2019 Jan; 111():62-70. PubMed ID: 29684595
[TBL] [Abstract][Full Text] [Related]
18. Elabela/Toddler and apelin bind differently to the apelin receptor.
Couvineau P; Llorens-Cortes C; Iturrioz X
FASEB J; 2020 Jun; 34(6):7989-8000. PubMed ID: 32301550
[TBL] [Abstract][Full Text] [Related]
19. [The role of apelin in pathogenesis of cardiovascular diseases and metabolic disorders].
Cudnoch Jędrzejewska A; Czarzasta K; Gomółka R; Szczepańska Sadowska E
Kardiol Pol; 2011; 69 Suppl 3():89-93. PubMed ID: 22125210
[TBL] [Abstract][Full Text] [Related]
20. Apelin/APJ system: A potential therapeutic target for endothelial dysfunction-related diseases.
Cheng J; Luo X; Huang Z; Chen L
J Cell Physiol; 2019 Aug; 234(8):12149-12160. PubMed ID: 30585633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
